A Phase 1 Pharmacokinetic and Safety Study of Extended Duration, High-Dose Cefixime for Cephalosporin-Resistant Neisseria Gonorrhoeae in the Pharynx
Sexually Transmitted Diseases- United States
doi 10.1097/olq.0000000000000844
Full Text
Abstract
Available in
Date
October 1, 2018
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)